Senseonics Holdings, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Senseonics Holdings, Inc. develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, Africa, and other international markets; its core products include the Eversense, Eversense XL, Eversense E3, and Eversense 365 implantable CGM systems, featuring a fully implantable under-the-skin sensor that provides glucose measurements for up to 365 days, a removable rechargeable smart transmitter, a mobile app for real-time monitoring with vibratory alerts and data sharing, and related accessories such as Eversense E3 Mobile App for displaying trends and caregiver connectivity. Founded in 1996 and headquartered in Germantown, Maryland, the company serves healthcare providers and patients through distributors, strategic fulfillment partners like Ascensia Diabetes Care, and collaborations such as with University Hospitals Accountable Care Organization and Mercy health system. Recent developments include FDA approval and U.S. commercialization of Eversense 365 in 2024, formation of a dedicated CGM division with partner Ascensia Diabetes Care, a partnership with Mercy health system to enhance diabetes outcomes and reduce costs, appointment of Brian Hansen as Chief Commercial Officer, and a September 2025 loan and security agreement providing up to $100 million in funding led by Hercules Capital, Inc. to support commercial expansion.
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
Senseonics Shares Sink Friday: What's Driving The Move?
Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
SENS Launches Eversense 365, World's Only One-Year CGM in Europe
Senseonics Announces European Launch of Eversense® 365, The World's First and Only One Year CGM System
Ralliant (NYSE:RAL) versus Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Head-To-Head Analysis
Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) vs. Ralliant (NYSE:RAL) Financial Survey